Now showing items 1-5 of 5

    • Between-region genetic divergence reflects the mode and tempo of tumor evolution. 

      Sun, R; Hu, Z; Sottoriva, A; Graham, TA; Harpak, A; Ma, Z; Fischer, JM; Shibata, D; Curtis, C (2017-07)
      Given the implications of tumor dynamics for precision medicine, there is a need to systematically characterize the mode of evolution across diverse solid tumor types. In particular, methods to infer the role of natural ...
    • Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. 

      Smyth, EC; Fassan, M; Cunningham, D; Allum, WH; Okines, AFC; Lampis, A; Hahne, JC; Rugge, M; Peckitt, C; Nankivell, M; Langley, R; Ghidini, M; Braconi, C; Wotherspoon, A; Grabsch, HI; Valeri, N (2016-08)
      PURPOSE:The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable ...
    • The molecular landscape of colitis-associated carcinogenesis. 

      Saraggi, D; Fassan, M; Mescoli, C; Scarpa, M; Valeri, N; Michielan, A; D'Incá, R; Rugge, M (2017-04)
      In spite of the well-established histopathological phenotyping of IBD-associated preneoplastic and neoplastic lesions, their molecular landscape remains to be fully elucidated. Several studies have pinpointed the initiating ...
    • Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. 

      Wang, Y; McKay, JD; Rafnar, T; Wang, Z; Timofeeva, MN; Broderick, P; Zong, X; Laplana, M; Wei, Y; Han, Y; Lloyd, A; Delahaye-Sourdeix, M; Chubb, D; Gaborieau, V; Wheeler, W; Chatterjee, N; Thorleifsson, G; Sulem, P; Liu, G; Kaaks, R; Henrion, M; Kinnersley, B; Vallée, M; LeCalvez-Kelm, F; Stevens, VL; Gapstur, SM; Chen, WV; Zaridze, D; Szeszenia-Dabrowska, N; Lissowska, J; Rudnai, P; Fabianova, E; Mates, D; Bencko, V; Foretova, L; Janout, V; Krokan, HE; Gabrielsen, ME; Skorpen, F; Vatten, L; Njølstad, I; Chen, C; Goodman, G; Benhamou, S; Vooder, T; Välk, K; Nelis, M; Metspalu, A; Lener, M; Lubiński, J; Johansson, M; Vineis, P; Agudo, A; Clavel-Chapelon, F; Bueno-de-Mesquita, HB; Trichopoulos, D; Khaw, K-T; Johansson, M; Weiderpass, E; Tjønneland, A; Riboli, E; Lathrop, M; Scelo, G; Albanes, D; Caporaso, NE; Ye, Y; Gu, J; Wu, X; Spitz, MR; Dienemann, H; Rosenberger, A; Su, L; Matakidou, A; Eisen, T; Stefansson, K; Risch, A; Chanock, SJ; Christiani, DC; Hung, RJ; Brennan, P; Landi, MT; Houlston, RS; Amos, CI (2014-07)
      We conducted imputation to the 1000 Genomes Project of four genome-wide association studies of lung cancer in populations of European ancestry (11,348 cases and 15,861 controls) and genotyped an additional 10,246 cases and ...
    • A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. 

      Battersby, NJ; Dattani, M; Rao, S; Cunningham, D; Tait, D; Adams, R; Moran, BJ; Khakoo, S; Tekkis, P; Rasheed, S; Mirnezami, A; Quirke, P; West, NP; Nagtegaal, I; Chong, I; Sadanandam, A; Valeri, N; Thomas, K; Frost, M; Brown, G (2017-08-29)
      Pre-operative chemoradiotherapy (CRT) for MRI-defined, locally advanced rectal cancer is primarily intended to reduce local recurrence rates by downstaging tumours, enabling an improved likelihood of curative resection. ...